Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 38,891,048
  • Shares Outstanding, K 106,080
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 895,520 K
  • 36-Month Beta 1.34
  • Price/Sales 8.11
  • Price/Cash Flow 36.97
  • Price/Book 8.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
360.00 +7.91%
on 04/27/17
401.21 -3.17%
on 03/29/17
+5.94 (+1.55%)
since 03/28/17
3-Month
342.16 +13.54%
on 01/30/17
401.21 -3.17%
on 03/29/17
+41.99 (+12.12%)
since 01/27/17
52-Week
325.35 +19.41%
on 11/04/16
452.96 -14.23%
on 11/14/16
-2.81 (-0.72%)
since 04/28/16

Most Recent Stories

More News
Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

BAYRY : 124.4280 (+1.48%)
GILD : 68.55 (-0.04%)
REGN : 388.49 (+5.97%)
SNY : 47.30 (+0.83%)
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up

Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician...

HSKA : 108.25 (+2.88%)
SRPT : 36.26 (+4.44%)
GILD : 68.55 (-0.04%)
REGN : 388.49 (+5.97%)
Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates

Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share....

HSKA : 108.25 (+2.88%)
MRK : 62.33 (-0.40%)
SGEN : 68.30 (+0.06%)
REGN : 388.49 (+5.97%)
Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

HSKA : 108.25 (+2.88%)
REGN : 388.49 (+5.97%)
AMGN : 163.32 (+0.37%)
SNY : 47.30 (+0.83%)
Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for Kevzara (sarilumab)...

SAN : 6.52 (+1.09%)
REGN : 388.49 (+5.97%)
SNY : 47.30 (+0.83%)
NASDAQ Pulls Away

NASDAQ Pulls Away

HUN : 24.77 (-1.39%)
MHK : 234.79 (-1.71%)
UTEK : 30.52 (-0.91%)
ADI : 76.20 (-2.12%)
CNC : 74.40 (+1.99%)
NSP : 91.35 (-1.56%)
RCL : 106.60 (+6.07%)
HAS : 99.11 (-1.40%)
REGN : 388.49 (+5.97%)
SGMS : 23.75 (+3.71%)
After Yesterday's Decline of 2.06%, Regeneron Pharmaceuticals Offers Investors Better Value

Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $360.00 to a high of $371.71. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day...

REGN : 388.49 (+5.97%)
Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

NVS : 77.03 (-0.04%)
REGN : 388.49 (+5.97%)
AMGN : 163.32 (+0.37%)
SNY : 47.30 (+0.83%)
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.

CELG : 124.05 (+0.06%)
VRTX : 118.30 (+0.75%)
BMRN : 95.84 (-0.44%)
GILD : 68.55 (-0.04%)
REGN : 388.49 (+5.97%)
AMGN : 163.32 (+0.37%)
BIIB : 271.21 (-1.94%)
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA)...

SAN : 6.52 (+1.09%)
REGN : 388.49 (+5.97%)
SNY : 47.30 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM....

See More

Support & Resistance

2nd Resistance Point 408.63
1st Resistance Point 398.56
Last Price 388.49
1st Support Level 373.36
2nd Support Level 358.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.